Wall Street analyst estimates for Medline Inc. (MDLN): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions.
Consensus price target
$44.20 (+10% vs price $40.35)
between $37.00 and $55.00 · 10 targets published in the last quarter
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $31.2B | $31.2B – $31.3B | $1.49 | 12 |
| 2027E | $33.7B | $33.5B – $33.8B | $1.56 | 15 |
| 2028E | $36.3B | $35.8B – $37.4B | $1.79 | 9 |
Figures in USD · consensus as of November 4, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (−2 sell to +2 buy) | 0.89 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.34 | ||
| 2026-08-05 | $0.50 | $0.35 | +41.9% |
| 2026-05-06 | $0.33 | $0.30 | +11.8% |
| 2026-02-25 | $0.22 | $0.24 | -5.6% |
| 2025-11-04 | $0.31 |
Valuation Ratios
| P/E Ratio | 60.22 |
| Price / Book | 4.50 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $21.45B | $23.23B | $25.51B | $28.43B |
| Cost of Revenue | $16.89B | $18.01B | $19.22B | $20.91B |
| Gross Profit | $4.56B | $5.22B | $6.29B | $7.52B |
| Research & Development | $58.0M | $60.0M | $67.0M | 0 |
| Selling, General & Admin | $3.62B | $3.81B | $4.04B | $4.52B |
| Operating Expenses | $3.69B | $3.78B | $4.07B | $5.31B |
| Operating Income | $870.0M | $1.44B | $2.23B | $2.21B |
| EBITDA | $1.85B | $2.59B | $3.53B | $2.26B |
| Interest Expense | $911.0M | $1.38B | $1.31B | $812.0M |
| Pre-tax Income | $10.0M | $264.0M | $1.25B | $1.25B |
| Income Tax | $35.0M | $30.0M | $46.0M | $91.0M |
| Net Income | -$25.0M | $234.0M | $1.20B | $1.16B |
| EPS | -$0.03 | $0.30 | $1.52 | $1.43 |
| EPS (Diluted) | -$0.03 | $0.30 | $1.52 | $1.43 |
| Shares Outstanding (Diluted) | 787.1 M | 787.1 M | 787.1 M | 812.0 M |
Price
| Price | $40.35 (closing price, November 4, 2026) |
| Market Cap | $35.4B |
| Exchange | NASDAQ |
| Country | US |
Related companies: COO · MMSI · ICUI · BDX · SOLV · TFX
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of MDLN: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks